Session: 904. Outcomes Research: Hemoglobinopathies: Poster III
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Method: Data from acute visits to the IC and ED for VOCs was abstracted from the electronic medical record at the 9 clinical sites. Sites were instructed to abstract data from all IC visits and from a randomly selected day a week at the ED over two years. Patient disposition was defined as the location patient was discharged after care and was recorded after the patient visit. Time to first dose was calculated by subtracting the check-in time from the first analgesic pain medication administration time. Disposition rates and average time of first dose was compared between IC and ED across all 9 sites using a chi square and T test.
Findings: Over the course of data collection, 3121 visit dispositions were documented, with 2545 visits to the IC and 576 visits to the ED across all 9 sites. Of the 2545 visits to the IC, 31 (1.2%) visits led to hospital admission (range across all 9 sites: 0-3.84%), whereas 229 of the 576 (39.75%) visits to the ED resulted in hospital admission (range across 6 sites: 1.3-86.9; X-squared = 24.71, df =1, p-value<0.001) and IC: X-squared = 2329.4, df = 1, p-value <0.001. The average time to first dose for ICs was 38.67±35.60 minutes, whereas the ED time to first dose had an average time of 104.79±95.11 ( p-value< 0.001 )and a confidence interval (CI) of (58.68, 73.55).
Discussion: These findings demonstrate the real-world effectiveness of infusion care compared to the ED for VOC in individuals with SCD. Individuals seen in the infusion center had significantly lower times to first dose and were less likely to be admitted to the hospital when compared to individuals seen in the ED. This data provides further support for varying models of infusion care in different settings. There is a continued need to identify best practices for implementing and expanding access for infusion care in individuals with SCD.
Disclosures: Boucher: Takeda Pharmaceuticals: Research Funding; CSL Behring: Research Funding. DeCastro: Novartis: Research Funding. Guarino: Novartis: Consultancy. Smith: Pfizer: Consultancy; Vertex: Honoraria. Lauriello: PCORI: Research Funding; HRSA: Research Funding. Little: Beam: Other: Research support directly and indirectly (through NASCC); Novartis: Other: Research support directly and indirectly (through NASCC); Pfizer: Other: Research support directly and indirectly (through NASCC); Novo-Nordisk: Other: Adjusications Committee; NASCC: Membership on an entity's Board of Directors or advisory committees; ASH: Research Funding; NHLBI: Honoraria, Research Funding. Lanzkron: Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other: Stock in Family trust; Pfizer: Consultancy; HRSA: Research Funding; GMI: Consultancy; CSL-Behring: Research Funding; Takeda: Research Funding; GBT: Research Funding; Merck: Consultancy; Novartis: Consultancy; Agios: Membership on an entity's Board of Directors or advisory committees; PCORI: Research Funding; Bluebird BIo: Membership on an entity's Board of Directors or advisory committees; Teva: Other: Stock in Family trust.
See more of: Oral and Poster Abstracts